Literature DB >> 11111831

Functions of neuronal adenosine receptors.

H L Haas1, O Selbach.   

Abstract

Endogenous adenosine in nervous tissue, a central link between energy metabolism and neuronal activity, varies according to behavioral state and (patho)physiological conditions, it may be the major sleep propensity substance. The functional consequences of activation of the four known adenosine receptors, A1, A2A, A2B and A3, are considered here. The mechanisms and electrophysiological actions, mainly those of the A1-receptor, have been extensively studied using in vitro brain-slice preparations. A1-receptor activation inhibits many neurons postsynaptically by inducing or modulating ionic currents and presynaptically by reducing transmitter release. A1-receptors are almost ubiquitous in the brain and affect various K+ (Ileak, IAHP), mixed cationic (Ih), or Ca2+ currents, through activation of Gi/o-proteins (coupled to ion channels, adenylyl cyclase or phospholipases). A2A-receptors are much more localized, their functional role in the striatum is only just emerging. A2B- and A3-receptors may be affected in pathophysiological events, their function is not yet clear. The cAMP-PKA signal cascade plays a central role in the regulation of both neural activity and energy metabolism. Under conditions of increased demand and decreased availability of energy (such as hypoxia, hypoglycemia and/or excessive neuronal activity), adenosine provides a powerful protective feedback mechanism. Interaction with adenosine metabolism is a promising target for therapeutic intervention in neurological and psychiatric diseases such as epilepsy, sleep, movement (parkinsonism or Huntington's disease) or psychiatric disorders (Alzheimer's disease, depression, schizophrenia or addiction).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11111831     DOI: 10.1007/s002100000314

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  44 in total

1.  Signaling by extracellular nucleotides and nucleosides.

Authors:  P Illes; K N Klotz; M J Lohse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-11       Impact factor: 3.000

2.  Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cells.

Authors:  B C Suh; T D Kim; J U Lee; J K Seong; K T Kim
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

Review 3.  Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.

Authors:  Jeremy Veenstra-VanderWeele; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

4.  Targeting the brain: focal delivery of natural anticonvulsant molecules.

Authors:  Andrey Mazarati
Journal:  Epilepsy Curr       Date:  2005 Nov-Dec       Impact factor: 7.500

5.  Test-retest stability of cerebral A1 adenosine receptor quantification using [18F]CPFPX and PET.

Authors:  David Elmenhorst; Philipp T Meyer; Andreas Matusch; Oliver H Winz; Karl Zilles; Andreas Bauer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-23       Impact factor: 9.236

6.  Cell-specific differential modulation of human trabecular meshwork cells by selective adenosine receptor agonists.

Authors:  Mike O Karl; Kim Peterson-Yantorno; Mortimer M Civan
Journal:  Exp Eye Res       Date:  2006-10-30       Impact factor: 3.467

7.  Cytoskeletal protein 4.1G binds to the third intracellular loop of the A1 adenosine receptor and inhibits receptor action.

Authors:  Dongcheng Lu; Henglin Yan; Timothy Othman; Christopher P Turner; Thomas Woolf; Scott A Rivkees
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

Review 8.  The role of glial adenosine receptors in neural resilience and the neurobiology of mood disorders.

Authors:  Dietrich van Calker; Knut Biber
Journal:  Neurochem Res       Date:  2005-10       Impact factor: 3.996

Review 9.  Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment.

Authors:  E S Vizi; A Fekete; R Karoly; A Mike
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

10.  A1 adenosine receptors mediate hypoxia-induced ventriculomegaly.

Authors:  Christopher P Turner; Meltem Seli; Laura Ment; William Stewart; Henglin Yan; Bjorn Johansson; Bertil B Fredholm; Michael Blackburn; Scott A Rivkees
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.